Literature DB >> 31698428

Resolvin the clot: DVT resolution through RvD4.

Michael Holinstat1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31698428      PMCID： PMC6839958          DOI： 10.1182/blood.2019002419

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis.

Authors:  Reheman Adili; Benjamin E Tourdot; Katherine Mast; Jennifer Yeung; John C Freedman; Abigail Green; Diane K Luci; Ajit Jadhav; Anton Simeonov; David J Maloney; Theodore R Holman; Michael Holinstat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-03       Impact factor: 8.311

2.  Venous thromboembolism: a public health concern.

Authors:  Michele G Beckman; W Craig Hooper; Sara E Critchley; Thomas L Ortel
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

Review 3.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

Review 4.  Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases.

Authors:  Wolf-Hagen Schunck; Anne Konkel; Robert Fischer; Karsten-Henrich Weylandt
Journal:  Pharmacol Ther       Date:  2017-11-07       Impact factor: 12.310

5.  Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA.

Authors:  Anne-Claire Duchez; Luc H Boudreau; Gajendra S Naika; James Bollinger; Clémence Belleannée; Nathalie Cloutier; Benoit Laffont; Raifish E Mendoza-Villarroel; Tania Lévesque; Emmanuelle Rollet-Labelle; Matthieu Rousseau; Isabelle Allaeys; Jacques J Tremblay; Patrice E Poubelle; Gérard Lambeau; Marc Pouliot; Patrick Provost; Denis Soulet; Michael H Gelb; Eric Boilard
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-23       Impact factor: 11.205

6.  Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis.

Authors:  K Martinod; T Witsch; K Farley; M Gallant; E Remold-O'Donnell; D D Wagner
Journal:  J Thromb Haemost       Date:  2016-02-05       Impact factor: 5.824

Review 7.  The expansive role of oxylipins on platelet biology.

Authors:  Jennifer Yeung; Megan Hawley; Michael Holinstat
Journal:  J Mol Med (Berl)       Date:  2017-05-20       Impact factor: 4.599

8.  Resolvin D4 attenuates the severity of pathological thrombosis in mice.

Authors:  Deya Cherpokova; Charlotte C Jouvene; Stephania Libreros; Elise P DeRoo; Long Chu; Xavier de la Rosa; Paul C Norris; Denisa D Wagner; Charles N Serhan
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

9.  Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.

Authors:  Tarec K Elajami; Romain A Colas; Jesmond Dalli; Nan Chiang; Charles N Serhan; Francine K Welty
Journal:  FASEB J       Date:  2016-04-27       Impact factor: 5.191

Review 10.  Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology.

Authors:  Jesmond Dalli; Charles N Serhan
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739
  10 in total
  2 in total

1.  Human leukocytes selectively convert 4S,5S-epoxy-resolvin to resolvin D3, resolvin D4, and a cys-resolvin isomer.

Authors:  Ashley E Shay; Robert Nshimiyimana; Bengt Samuelsson; Nicos A Petasis; Jesper Z Haeggström; Charles N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-21       Impact factor: 12.779

Review 2.  E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.

Authors:  Charles N Serhan; Stephania Libreros; Robert Nshimiyimana
Journal:  Semin Immunol       Date:  2022-02-16       Impact factor: 11.130
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.